Table 2 Anatomical distribution of sarcoidosis lesions on FLT- and FDG-PET (N = 14)
Anatomical site | FLT-PET | FDG-PET | p value | Agreement† |
|---|---|---|---|---|
Lymph nodes | ||||
Thoracic | 10/14 (71%) | 10/14 (71%) | 0.99 | 0.65 (95% CI 0.21 to 1.0) |
Cervical | 7/14 (50%) | 8/14 (57%) | 0.72 | 0.29 (95% CI − 0.21 to 0.78) |
Abdominal/pelvic | 1/14 (7.1%) | 5/14 (36%) | 0.077 | 0.32 (95% CI − 0.18 to 0.81) |
Heart | ||||
Left ventricle | 6/14 (43%) | 7/14 (50%) | 0.72 | 0.86 (95% CI 0.59 to 1.0) |
Right ventricle | 2/14 (14%) | 4/14 (29%) | 0.38 | 0.59 (95% CI 0.11 to 1.0) |
Central nervous system | ||||
Intracranial | 1/14 (7.1%) | 0/14 (7.1%) | 0.33 | 0.0 (95% CI 0.0 to 0.0) |
Spinal/paraspinal | 1/14 (7.1%) | 1/14 (7.1%) | 0.99 | 1.0 (95% CI 1.0 to 1.0) |
Lung parenchyma | ||||
– | 5/14 (36%) | 5/14 (36%) | 0.99 | 0.69 (95% CI 0.29 to 1.0) |
Salivary glands | ||||
– | 0/14 (0%) | 1/14 (7.1%) | 0.33 | − 0.11 (95% CI − 0.26 to 0.04) |
Spleen | ||||
– | 0/14 (0%) | 1/14 (7.1%) | 0.33 | 0.0 (–) |
Liver | ||||
– | 0/14 (0%) | 0/14 (0%) | – | – |
Bone | ||||
– | 0/14 (0%) | 0/14 (0%) | – | – |
Average number of sites/per subject with active disease | ||||
– | 1.6 (1.0) | 1.8 (1.3) | 0.75 | 0.78 (95% 0.45 to 0.93) |